journal
MENU ▼
Read by QxMD icon Read
search

Leukemia & Lymphoma

journal
https://www.readbyqxmd.com/read/29334312/targeting-of-phospho-eif4e-by-homoharringtonine-eradicates-a-distinct-subset-of-human-acute-myeloid-leukemia
#1
Hong Zhou, Rong Zhen Xu, Ying Gu, Peng Fei Shi, Shenxian Qian
More than half of the patients with acute myeloid leukemia (AML) fail to achieve long-term disease-free survival with current therapies and novel therapeutic strategies are urgently needed. The effects of homoharringtonine (HHT) on the growth of AML cell lines and primary leukemia cells were examined using MTT, colony formation assay. The effects of HHT on both eukaryotic translation initiation factor 4E (eIF4E) and phospho-eIF4E(p-eIF4E) were examined through western blot and immunofluorescence staining. HHT selectively reduced levels of p-eIF4E and its downstream oncoprotein Mcl-1, and potently inhibited in vitro and in vivo the growth of a distinct subset of AML cells and primary leukemia cells expressing high level of p-eIF4E through apoptosis...
January 15, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29334300/the-impact-of-early-molecular-response-in-children-and-adolescents-with-chronic-myeloid-leukemia-treated-with-imatinib-a-single-center-study-from-china
#2
Haigang Shao, Zhao Zeng, Jiannong Cen, Jun Zhang, Shuxiao Bai, Chunxiao Wu, Yanlei Gong, Yong Wang, Huiying Qiu, Suning Chen, Jinlan Pan
Chronic myeloid leukemia (CML) is rare among children and adolescents. The early molecular response (EMR) is an important prognostic significance for adult CML patients. This study explored the impact of EMR on the prognosis in 40 children and adolescents with CML-CP treated with imatinib (IM). Our results showed that a high proportion of patients failed to achieve the BCR-ABL1/ABL1 International Scale (IS) ≤ 10% at 3 months. Children with a BCR-ABL1/ABL1 ≤ 10% at 3 months and <1% at 6 months increased the rate of achieving complete cytogenetic response (CCyR) and/or major molecular response (MMR) at 12 months compared to those with BCR-ABL1/ABL1 > 10%...
January 15, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29334284/surface-endoglin-cd105-expression-on-acute-leukemia-blast-cells-an-extensive-flow-cytometry-study-of-1002-patients
#3
Vincenzo Cosimato, Giulia Scalia, Maddalena Raia, Laura Gentile, Vincenza Cerbone, Feliciano Visconte, Teodora Statuto, Luciana Valvano, Fiorella D'Auria, Giovanni Calice, Daniela Graziano, Pellegrino Musto, Luigi Del Vecchio
No abstract text is available yet for this article.
January 15, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29322849/safety-profile-of-lenalidomide-in-patients-with-lower-risk-myelodysplastic-syndromes-without-del-5q-results-of-a-phase-3-trial
#4
Antonio Almeida, Pierre Fenaux, Guillermo Garcia-Manero, Stuart L Goldberg, Stefanie Gröpper, Anna Jonasova, Norbert Vey, Carmen Castaneda, Jianhua Zhong, C L Beach, Valeria Santini
The safety profile of lenalidomide use in lower-risk myelodysplastic syndromes (MDS) patients with del(5q) is well-established, but less is known in non-del(5q) patients. We provide safety data from a randomized, phase 3 trial evaluating lenalidomide in 239 patients with lower-risk non-del(5q) MDS ineligible/refractory to erythropoiesis-stimulating agents (ESAs). Compared with placebo, lenalidomide was associated with a higher incidence of grade 3-4 treatment-emergent adverse events (TEAEs; 86% vs. 44%), but not risk of infection (p = ...
January 11, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29322846/pi3k-akt-mtor-pathway-in-multiple-myeloma-from-basic-biology-to-clinical-promise
#5
Vijay Ramakrishnan, Shaji Kumar
Multiple myeloma (MM), a cancer of terminally differentiated plasma cells, is the second most common hematological malignancy. The disease is characterized by the accumulation of abnormal plasma cells in the bone marrow that remains in close association with other cells in the marrow microenvironment. In addition to the genomic alterations that commonly occur in MM, the interaction with cells in the marrow microenvironment promotes signaling events within the myeloma cells that enhances survival of MM cells...
January 11, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29322838/chronic-myelomonocytic-leukemia-with-central-nervous-system-involvement
#6
Michelle Hannon, Lindsay Wilde, Nneamaka Nwaoduah, Margaret Kasner
No abstract text is available yet for this article.
January 11, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29322835/toxic-epidermal-necrolysis-versus-cutaneous-graft-versus-host-disease-in-a-hematopoietic-stem-cell-transplant-recipient-the-role-of-elafin
#7
Alessandra Chen, Kevin Chao, Lina Rodriguez, William Munday, Scott Worswick
No abstract text is available yet for this article.
January 11, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29320913/a-phase-2-study-of-rituximab-cyclophosphamide-bortezomib-and-dexamethasone-r-cybord-in-relapsed-low-grade-and-mantle-cell-lymphoma
#8
Mohamad Bassam Sonbol, Talal Hilal, Amylou C Dueck, Allison C Rosenthal, Christopher R Conley, Heidi E Kosiorek, Brenda F Ginos, Katherine M Gano, Craig S Nichols, Jose F Leis, Patrick B Johnston, Thomas M Habermann, Donald W Northfelt, Peter Leif Bergsagel, David J Inwards, Thomas E Witzig, Stephen M Ansell, Craig B Reeder
In this phase 2 trial, we sought to evaluate the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) in patients with low-grade NHL. The regimen included rituximab on day 1 with weekly cyclophosphamide, dexamethasone, and bortezomib 1.3 mg/m2 IV in a 28-day cycle. Twenty one patients were enrolled on the study. Median age was 69 years (range 51-80) and 17 (81%) patients had two or more prior treatments. Histologies included FL (n = 8), MCL (n = 8), and LPL/WM (n = 5)...
January 10, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29320902/cd33-splicing-snp-regulates-expression-levels-of-cd33-in-normal-regenerating-monocytes-in-aml-patients
#9
Jatinder K Lamba, Andrew P Voigt, Lata Chauhan, Miyoung Shin, Richard Aplenc, Lisa Eidenschink Brodersen, Alan S Gamis, Soheil Meshinchi, Michael R Loken
No abstract text is available yet for this article.
January 10, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29316841/testicular-plasmacytoma-unique-location-or-circumstantial-presentation
#10
Eli Muchtar, Joan Bladé, Morie A Gertz
No abstract text is available yet for this article.
January 9, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29308723/current-systemic-therapeutic-options-for-advanced-mycosis-fungoides-and-s%C3%A3-zary-syndrome
#11
Jenna Janiga, Jonathan Kentley, Chadi Nabhan, Farah Abdulla
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common cutaneous T-cell lymphomas (CTCLs). Both lack curative options, and advanced-stage carries a poor prognosis. Whilst there are a number of treatments available, achieving and maintaining a durable remission remains challenging. We review current systemic treatment options as monotherapy for advanced-stage MF (IIB-IV), appraising their mechanism of action, analyzing their efficacy, and describing toxicities. Individually, reported overall response rates (ORR) vary widely in the literature and duration of responses are typically short, ranging from 7...
January 8, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29308691/predictive-biomarkers-and-practical-considerations-in-the-management-of-carflizomib-associated-cardiotoxicity
#12
Nikoletta Lendvai, Ioanna Tsakos, Sean M Devlin, Wendy L Schaffer, Hani Hassoun, Alexander M Lesokhin, Heather Landau, Neha Korde, Sham Mailankody, Eric Smith, David J Chung, Guenther Koehne, Gunjan L Shah, Aeri Alexander, Minal Patel, Andrea Ballagi, Ida Grundberg, Sergio A Giralt, Ola Landgren
No abstract text is available yet for this article.
January 8, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29303024/bortezomib-in-combination-with-dose-adjusted-epoch-etoposide-prednisone-vincristine-cyclophosphamide-and-doxorubicin-induces-long-term-survival-in-patients-with-plasmablastic-lymphoma-a-retrospective-analysis
#13
Christopher Dittus, Natalie Grover, Steven Ellsworth, Xianming Tan, Steven I Park
Plasmablastic lymphoma (PBL) is a rare and aggressive form of B-cell non-Hodgkin lymphoma. This subtype of lymphoma has a post-germinal center cell-of-origin called the plasmablast, and the immunophenotype is more consistent with that of a plasma cell than a lymphocyte. Because of these unique features, PBL is notoriously difficult to treat. Case reports and small reviews have evaluated the addition of agents directed against plasma cell disorders in combination with traditional lymphoma-directed regimens. We describe the largest case series to date, with the longest follow-up, evaluating bortezomib in combination with etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (V-EPOCH) for the treatment of PBL...
January 5, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29295653/improvement-of-fatigue-physical-functioning-and-well-being-among-patients-with-severe-impairment-at-baseline-receiving-ibrutinib-in-combination-with-bendamustine-and-rituximab-for-relapsed-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-in-the-helios
#14
Paula Cramer, Graeme Fraser, Rodrigo Santucci-Silva, Sebastian Grosicki, Marie-Sarah Dilhuydy, Ann Janssens, Javier Loscertales, Simon Rule, Andre Goy, Shana Traina, Eric K H Chan, Joris Diels, Nishan Sengupta, Michelle Mahler, Mariya Salman, Angela Howes, Asher Chanan-Khan
Health-related quality of life (HRQoL) is an important endpoint, especially in clinical trials for malignancies with a long course of disease, such as chronic lymphocytic leukemia (CLL). Patient-reported outcomes were examined in the randomized, double-blind, placebo-controlled HELIOS study to assess the impact of treatment with the Bruton's tyrosine kinase inhibitor ibrutinib, added to bendamustine plus rituximab (BR) background therapy. Measures included FACIT-Fatigue, EORTC QLQ-C30, QLQ-CLL16, and EQ-5D-5L...
January 3, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29295648/incidence-racial-disparities-and-survival-outcomes-of-mast-cell-malignancies-analysis-from-a-national-database
#15
Anuhya Kommalapati, Yevgeniya Kushchayeva, Sri Harsha Tella
No abstract text is available yet for this article.
January 3, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29295645/favorable-immune-signature-in-cll-patients-defined-by-antigen-specific-t-cell-responses-might-prevent-second-skin-cancers
#16
Juliane Sarah Walz, Daniel Johannes Kowalewski, Linus Backert, Annika Nelde, Oliver Kohlbacher, Benjamin Weide, Lothar Kanz, Helmut Rainer Salih, Hans-Georg Rammensee, Stefan Stevanović
The course of chronic lymphocytic leukemia (CLL), inducing an immunosuppressed state that also affects T cells as central components of adaptive immunity, predisposes patients to develop second malignancies with skin cancer being the most common. Recently, we found that prevalence of memory T cells with specificity for CLL-associated antigens defined by mass spectrometry-based immunopeptidome analysis correlated with a significant survival benefit. Here, we analyzed our CLL patient cohort for second skin (pre)malignancies and found a significantly lower incidence of skin cancer in the patients showing immune responses to CLL-associated antigens...
January 3, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29295644/coincidence-of-5q-deletion-and-the-jak2v617f-mutation-report-of-two-patients-with-overlapping-myelodysplastic-and-myeloproliferative-features-and-review-of-the-literature
#17
Susanne Bürki, Evgenii Shumilov, Nicolas Bonadies, Johanna Flach, Myriam Legros, Yara Banz, Elisabeth Oppliger-Leibundgut, Martin Fiedler, Anne Angelillo-Scherrer, Alicia Rovo, Ulrike Bacher
No abstract text is available yet for this article.
January 3, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29295643/the-genomic-landscape-of-two-burkitt-lymphoma-cases-and-derived-cell-lines-comparison-between-primary-and-relapse-samples
#18
Claudia M Wever, Dominique Geoffrion, Bruno M Grande, Stephen Yu, Miguel Alcaide, Maryse Lemaire, Yasser Riazalhosseini, Josée Hébert, Christina Gavino, Donald C Vinh, Tina Petrogiannis-Haliotis, Svetlana Dmitrienko, Koren K Mann, Ryan D Morin, Nathalie A Johnson
Relapse occurs in 10-40% of Burkitt lymphoma (BL) patients that have completed intensive chemotherapy regimens and is typically fatal. While treatment-naive BL has been characterized, the genomic landscape of BL at the time of relapse (rBL) has never been reported. Here, we present a genomic characterization of two rBL patients. The diagnostic samples had mutations common in BL, including MYC and CCND3. Additional mutations were detected at relapse, affecting important pathways such as NFκB (IKBKB) and MEK/ERK (NRAS) signaling, glutamine metabolism (SIRT4), and RNA processing (ZFP36L2)...
January 3, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29295642/clinical-characteristics-therapy-response-and-outcome-of-51-adult-patients-with-hematological-malignancy-associated-hemophagocytic-lymphohistiocytosis-a-single-institution-experience
#19
Fryderyk Lorenz, Monika Klimkowska, Ewa Pawłowicz, Agnes Bulanda Brustad, Martin Erlanson, Maciej Machaczka
Hemophagocytic lymphohistiocytosis (HLH) is an underdiagnosed but life-threatening syndrome of hyperinflammation often occurring in adults with hematological malignancies (hM-HLH). The aim of the study was to describe clinical characteristics, therapy response, and outcome of adults with hM-HLH. The study included 51 adults with hM-HLH aged 23-84 years. Hyperferritinemia ≥500 µg/L was present in 96% of patients. The serum concentration of sIL-2Rα ≥ 2400 U/mL was revealed in 94% of patients. Twenty-three patients (45%) responded to therapy and achieved remission of HLH...
January 3, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29295650/amifostine-reduces-gastro-intestinal-toxicity-after-autologous-transplantation-for-multiple-myeloma
#20
Ehsan Malek, Vinita Gupta, Richard Creger, Paolo Caimi, Anant Vatsayan, Fahrettin Covut, Qaiser Bashir, Richard Champlin, Ruby Delgado, Gabriela Rondon, Brenda Cooper, Marcos de Lima, Hillard M Lazarus, Muzaffar Qazilbash
High-dose melphalan (HDM) followed by autologous hematopoietic cell transplantation (auto-HCT) remains the standard-of-care therapy for multiple myeloma (MM) even with the availability of proteasome inhibitors and immunomodulatory drugs. Gastrointestinal (GI) toxicity is the main cause of morbidity after HDM. Amifostine, a cytoprotective agent, may reduce HDM-associated GI toxicity. We conducted a case control study comparing HDM + auto-HCT with or without amifostine for MM patients. One hundred and seven patients treated at University Hospitals Cleveland Medical Center who received pre-transplant amifostine were compared to 114 patients treated at MD Anderson Cancer Center without use of this agent...
January 2, 2018: Leukemia & Lymphoma
journal
journal
30440
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"